List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 60 studies with search of: Etravirine OR TMC125 OR Intelence[TREATMENT] AND HIV [CONDITION]
Hide studies that are not seeking new volunteers.
Hide studies with unknown recruitment status.
  Display Options
Rank Status Study
1 Completed TMC125-C229: TMC125 in HIV-1 Infected Subjects, Who Were Randomized to a TMC125 Treatment Arm in a Sponsor Selected TMC125 Trial and Were Treated for at Least 48 Weeks
Condition: HIV Infection
Intervention: Drug: TMC-125
2 Completed TMC 125 Blood Levels Study
Condition: HIV Infections
Interventions: Drug: TMC125 once daily;   Drug: TMC125 twice daily
3 Completed TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.
Conditions: HIV;   AIDS;   Fungal Infection
Intervention: Drug: TMC125
4 Completed TMC125-C211: Trial of TMC125 in HIV-1 Infected Subjects Who Were in a Sponsor Selected TMC125 Trial
Condition: HIV Infection
Intervention: Drug: TMC125
5 Completed TMC125-C223: TMC125 in HIV-1 Infected Subjects
Condition: HIV Infection
Intervention: Drug: TMC125
6 Completed TMC125-C227: A Phase II Randomized, Active-Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-Naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use
Condition: HIV Infection
Intervention: Drug: TMC125
7 Completed TMC125-TiDP2-C188: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Effect of Multiple-dose TMC125 on Buprenorphine and Norbuprenorphine Administered in HIV-negative Patients on Stable Buprenorphine/Naloxone Maintenance Therapy.
Conditions: HIV;   Pharmacokinetics
Intervention: Drug: TMC125
8 Active, not recruiting An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).
Condition: HIV-1
Intervention: Drug: TMC125
9 Recruiting A Study to Assess the Pharmacokinetics (Blood Levels) of TMC114 (Darunavir) Taken With TMC114r (Ritonavir), and TMC125 (Etravirine) in HIV-1 Infected Pregnant Women
Conditions: HIV;   HIV Infections;   Pregnancy
Interventions: Drug: TMC114 (darunavir);   Drug: TMC114r (ritonavir);   Drug: TMC125 (etravirine)
10 Completed TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.
Condition: HIV
Interventions: Drug: TMC125;   Drug: Placebo
11 Completed TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.
Condition: HIV
Interventions: Drug: TMC125;   Drug: Placebo
12 Completed TMC125-TiDP2-C197: A Phase I Trial to Investigate the Pharmacokinetic Interaction Between Lopinavir/Ritonavir and TMC125 Both at Steady-state in Healthy Volunteers.
Condition: HIV
Intervention: Drug: Etravirine; Lopinavir; Ritonavir
13 Completed TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents.
Condition: HIV-1
Intervention: Drug: TMC125
14 Approved for marketing The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.
Condition: HIV-1
Intervention: Drug: TMC125
15 Completed TMC125-C203: Phase II Randomized (Patients Are Assigned Different Treatments Based on Chance), Placebo Controlled Dose Escalating Trial of TMC125 in HIV-1 Infected Patients
Conditions: Anti-Retroviral Agents;   HIV-1
Intervention: Drug: TMC125
16 Completed
Has Results 		A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment).
Condition: HIV-1 Infection
Intervention: Drug: TMC125; darunavir; ritonavir
17 Completed
Has Results 		Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.
Condition: HIV
Intervention: Drug: TMC125, Darunavir; Ritonavir
18 Completed
Has Results 		A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients
Conditions: HIV Infection;   HIV;   Acquired Immunodeficiency Syndrome
Interventions: Drug: etravirine (ETR, TMC125);   Drug: efavirenz (EFV)
19 Completed Pilot Study Switching Individuals Receiving EFV With Continuing Central Nervous System Toxicity to TMC125
Condition: HIV
Interventions: Drug: Etravirine;   Drug: Efavirenz
20 Active, not recruiting TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients
Conditions: HIV Infections;   Acquired Immunodeficiency Syndrome
Interventions: Drug: 48 weeks ATV/rtv 300/100mg once daily + ETR 200mg twice daily;   Drug: TDF 300mg;   Drug: ATV/rtv 400/100mg;   Drug: ATV/rtv 300/100mg

Previous Page Studies Shown (1-20) Next Page (21-40)
† Indicates status has not been verified in more than two years
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services